Pioglitazone , ≥98% , 111025-46-8
CAS NO.：111025-46-8
Empirical Formula: C19H20N2O3S
Molecular Weight: 356.44
MDL number: MFCD00865504
EINECS: 601-029-7
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB353.60 | In Stock |
|
| 50MG | RMB708.00 | In Stock |
|
| 250MG | RMB1276.80 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 183-184 C |
| Boiling point: | 575.4±45.0 °C(Predicted) |
| Density | 1.260±0.06 g/cm3(Predicted) |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C |
| solubility | DMSO (Slightly, Heated) |
| pka | 6.35±0.50(Predicted) |
| form | White to off-white solid. |
| color | White to Off-White |
Description and Uses
Pioglitazone is an agonist of the peroxisome proliferator-activated receptor γ (PPARγ; EC50 = ~500-600 nM for both human and murine PPARγ). It is selective for PPARγ over PPARα, exhibiting low level activation of PPARα at 1 μM and 5.4-fold activation at a concentration of 10 μM. Pioglitazone inhibits pyruvate oxidation and glucose production in hepatocytes when used at a concentration of 10 μM. In vivo, pioglitazone (0.3-3 mg/kg per day) reduces hyperglycemia, hyperlipidemia, and hyperinsulinemia in a dose-dependent manner in male Wistar fatty rats. It reduces the number of lesions in a transgenic rat adenocarcinoma of prostate (TRAP) model. Pioglitazone (2.5 mg/kg) also decreases production of neuroinflammatory cytokines and reduces immobility in the forced swim and tail suspension tests in a mouse model of chronic mild stress, indicating antidepressant-like activity that can be reversed by the PPARγ antagonist GW9662 .
antihyperlipidemic, HMGCoA reductase inhibitor
Safety
| Symbol(GHS) |   GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302-H312-H332-H351-H361 |
| Precautionary statements | P280 |
| Hazard Codes | F,C |
| Risk Statements | 11-34 |
| Safety Statements | 16-26-36/37/39-45 |
